<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: (1) To measure the proportion of participants who used hypoglycaemic agents provided by CDAP only, for at least 6 months, and attained an HbA1c of &lt;or=7% (a measure of glycaemic control) and (2) to determine the attitudes and practices of patients and pharmacist in this new programme </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: The attainment of a glycosylated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA1c) concentration of &lt;or=7% in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> was used as a measure of good glycaemic control </plain></SENT>
<SENT sid="2" pm="."><plain>Consequently we measured the HbA1c in 208 subjects who satisfied the entry criteria </plain></SENT>
<SENT sid="3" pm="."><plain>Two questionnaires were designed, pre-tested and administered to both patients and pharmacist in the programme to determine their attitudes and practices </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of the 208 eligible participants, 128 (61.5%) were well controlled, 94% of <z:hpo ids='HP_0000001'>all</z:hpo> participants were satisfied with CDAP and only 23.3% of participants experienced one or more minor side effect with the drugs used from CDAP </plain></SENT>
<SENT sid="5" pm="."><plain>There were no significant differences between patients who were well controlled and poorly controlled with respect to gender, physical activity and diet </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The study demonstrated that CDAP has impacted favorably on the control of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> in Trinidad, most participants were satisfied with the programme and there were no major adverse effects from the drugs used </plain></SENT>
</text></document>